After manufacturing issues led ADMA Biologics to pull its primary immune deficiency disease drug Bivigam from the market, it's won a new FDA approval.

With an Ebola outbreak in Congo outrunning vaccination efforts, the WHO wants to use an experimental drug from Johnson & Johnson.

Novartis may be struggling a bit in the U.S. with cancer drug launches, but it has a new market it can now explore: Saudi Arabia.

Merck & Co., which has been riding a wave of Gardasil sales, will invest $1 billion and add 100 jobs to expand production.

Drug distributor McKesson, which has had serious opioid habits, has settled another lawsuit tying it to the nation’s opioid problems.  

India’s Cadila found a ray of sunshine in the fact that the FDA issued 14 observations during an inspection of its formulation plant in Moraiya.

The U.S. is seeing a spike in measles cases, but Merck, the sole producer of the measles vaccine for the U.S., says it has production in hand.

Heron Therapeutics has received a complete response letter for its pain drug candidate because the FDA had issues about CMC processes.